Your browser doesn't support javascript.
loading
Investigating outcome measures for assessing airway clearance techniques in adults with cystic fibrosis: protocol of a single-centre randomised controlled crossover trial.
Stanford, Gemma; Davies, Jane C; Usmani, Omar; Banya, Winston; Charman, Susan; Jones, Mandy; Simmonds, Nicholas J; Bilton, Diana.
Affiliation
  • Stanford G; Adult Cystic Fibrosis, Royal Brompton Hospital, London, UK.
  • Davies JC; National Heart and Lung Institute, Imperial College London, London, UK.
  • Usmani O; National Heart and Lung Institute, Imperial College London, London, UK.
  • Banya W; Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK.
  • Charman S; National Heart and Lung Institute, Imperial College London, London, UK.
  • Jones M; Research and Development, Royal Brompton Hospital, London, UK.
  • Simmonds NJ; National Heart and Lung Institute, Imperial College London, London, UK.
  • Bilton D; Research and Development, Royal Brompton Hospital, London, UK.
BMJ Open Respir Res ; 7(1)2020 10.
Article in En | MEDLINE | ID: mdl-33020113
ABSTRACT

INTRODUCTION:

Airway clearance techniques (ACTs) are a gold standard of cystic fibrosis management; however, the majority of research evidence for their efficacy is of low standard; often attributed to the lack of sensitivity from outcome measures (OMs) used historically. This randomised controlled trial (RCT) investigates these standard OMs (sputum weight, forced expiratory volume in 1 s) and new OMs (electrical impedance tomography (EIT), multiple breath washout (MBW) and impulse oscillometry (IOS)) to determine the most useful measures of ACT. METHODS AND

ANALYSIS:

This is a single-centre RCT with crossover design. Participants perform MBW, IOS and spirometry, and then are randomised to either rest or supervised ACT lasting 30-60 min. MBW, IOS and spirometry are repeated immediately afterwards. EIT and sputum are collected during rest/ACT. On a separate day, the OMs are performed with the other intervention. Primary endpoint is difference in change in OMs before and after ACT/rest. Sample size was calculated with 80% power and significance of 5% for each OM (target n=64). ETHICS AND DISSEMINATION Ethics approval was gained from the London-Chelsea Research Ethics Committee (reference 16/LO/0995, project ID 154635). Dissemination will involve scientific conference presentation and publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBERS ISRCTN11220163 and NCT02721498.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cystic Fibrosis Type of study: Clinical_trials Aspects: Ethics Limits: Adult / Humans Language: En Journal: BMJ Open Respir Res Year: 2020 Document type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cystic Fibrosis Type of study: Clinical_trials Aspects: Ethics Limits: Adult / Humans Language: En Journal: BMJ Open Respir Res Year: 2020 Document type: Article Affiliation country: United kingdom